Target preference of 15 quinolones against Staphylococcus aureus, based on antibacterial activities and target inhibition

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 12, 2001, Pages 3544-3547

  Takei, M ^a   Fukuda, H ^a   Kishii, R ^a   Hosaka, M ^a  

^a KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; DNA TOPOISOMERASE IV; ENOXACIN; FLEROXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; LOMEFLOXACIN; MOXIFLOXACIN; NADIFLOXACIN; NORFLOXACIN; OFLOXACIN; PAZUFLOXACIN; QUINOLONE; QUINOLONE DERIVATIVE; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG MECHANISM; DRUG PROTEIN BINDING; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

4-QUINOLONES; ANTI-INFECTIVE AGENTS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA, SUPERHELICAL; ENZYME INHIBITORS; MICROBIAL SENSITIVITY TESTS; MUTATION; STAPHYLOCOCCUS AUREUS;

EID: 0035180501     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.12.3544-3547.2001     Document Type: Article

References (19)

1. DNA gyrase, topoisomerase IV, and the 4-quinolones
2. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: A primary target of fluoroquinolones
3. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus
4. Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the nora transformant of Staphylococcus aureus
5. Primary targets of fluoroquinolones in Streptococcus pneumoniae
6. Mechanisms of action and resistance of older and newer fluoroquinolones
7. Sequential acquisition of norfloxacin and ofloxacin resistance by methicillin-resistant and -susceptible Staphylococcus aureus
8. Quinolone resistance mutations in topoisomerase IV: Relationship to the flqa locus and genetic evidence that topoisomerase IV is the primary target and DNA gyrase is the secondary target of fluoroquinolones in Staphylococcus aureus
9. Roles of DNA topoisomerases in chromosomal replication and segregation
10. Dual inhibitory activity of sitafloxacin (DU-6859α) against DNA gyrase and topoisomerase IV of Streptococcus pneumoniae
11. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
12. DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae
13. Type II DNA topoisomerases as antibacterial targets
14. Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian type II topoisomerases
15. Inhibitory activities of quinolones against DNA gyrase and topoisomerase IV purified from Staphylococcus aureus
16. ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae
17. Antimicrobial evaluation of nadifloxacin (OPC-7251), a new topical quinolone, in acne vulgaris
18. Alterations in DNA topoisomerase IV grL4 gene responsible for quinolone resistance in Staphylococcus aureus